학술논문
여성 골반 염증성 질환의 치료에 있어 Cefbuperazone의 임상효과
The Clinical Evaluation of Cefbuperazone (Tomiporan) in the Treatment of Female Pelvic Inflammatory Disease
The Clinical Evaluation of Cefbuperazone (Tomiporan) in the Treatment of Female Pelvic Inflammatory Disease
Document Type
Article
Source
Obstetrics & Gynecology Science. May 30, 1994 37(5):937
Subject
Language
Korean
ISSN
2287-8572
Abstract
본 연구는 1991년 8월부터 1992년 7월까지 연세대학교 의과대학 부속 세브란스병원 산부인과에 내원하여 여성 골반 염증성 질환으로 진단된 환자 40례를 대상으로 혈액, 뇨, 자궁 경부, 더글라스와로부터 검체를 분리하여 ampicillin, cephalothin 및 cefbuperazone 등으로 약제 감수성 검사를 시행하여 비교하였고, 분리 균주에 대한 cefbuperazone의 최소 억제 농도를 측정하였으며 cefbuperazone 투약후균의 소실율을 관찰하여 다음과 같은 결과를 얻었다. 1. 환자의 연령 분포는 19세에서 49세였고 평균연령은 34.0로 20대가 45%, 30대가 35%로서 가임여성에서 호발하였다. 2. 자궁경부 및 더글라스와 천자 검체에서 분리된 균주는 총 47주로서 균주분포를 보면 Gonococcus가 7주, E.coli, Enterococcus 및 Staphylococcus Gardnerella가 각각 6주, Lactobacilli, Bacteroides가 각각 5주와 3주 등이었으며, 그람음성이 40.4%, 혐기성균이 31.9%, 그람 양성균이 27.7%로서 그람 음성균 및 혐기성균의 차지율이 높게 나타났다. 3. ampicllin, cephalothin, cefbuperazone약제에 대한 감수성 검사 비교결과 Enterococci는 ampicillin에 대해 100%의 감수성을 보였을 뿐, 이균을 제외한 다른 모든 균주의 경우 ampicillin 은 0에서 50%, cephalothin은 33에서 100%까지의 다양한 감수성을 보인데 비해서 cefbuperazone은 모든 균주에 대해 100%의 감수성을 나타내어 Enterococcus를 제외한 모든 균주에 대하여 ampicillin 및 cephalothin보다 우수한 감수성을 보이는 것으로 나타났다. 4. 분리 균주에 대한 cefbuperazone의 최소 억제농도는 Enterococci를 제외한 나머지 균주에서 4 micro g/mL이하였다. 5. cefbuperazone 투약전에 분리된 총 47균주중 39균주에서 투약후 균의 소실률을 관찰한 결과 82.7%의 균 소실률을 보였으며 투약후에도 계속 잔재되어 있는 균주는 8주로서 17.3%였다. 6. 임상효과의 판정은 100%의 유효율을 보였다. 7. 투약 전후의 임상적 검사에 의한 간 및 신장기능의 변화는 없었으며 특이할만한 부작용도 없었다. 이상의 결과로 여성 골반 염증성 질환의 약물 치료에 있어서 cefbuperazone은 임상적으로 우수한 항균 효과와 안정성이 높은 약제로 사료된다.
This study was examined to evaluate the clinical efficacy of the cefbuperazone in 40 patients with pelvic inflammatory disease, who visited the department of obstetrics and gynecology, Yonsei university college of medicine from August 1991 through July 1992. The mean age of the patients was 34.0 years (range 19 to 40 years). The total isolated organisms were 47 strains. Among them the aerobes were 32 strains (68.1%) and the anaerobes were 15 strains (31.9%). Bacteriological response of cefbuperazone was superior than that of ampicllin & cephalothin in vitro susceptability tests. The cefbuperazone was sensitive to all isolated organisms except enterococcus which was more sensitive to ampicillin. Minimum inhibitory concentration (MIC) of cefbuperazone for most of the isolated organisms except enterococcus was less than 4 micro g/ml. The eradication rate, in the bacteriologic response of cefbuperazone, was 82.7%, and the clinical efficacy rate of cefbuperazone was 100%. There was no remarkable side effect. Our results suggest that the cefbuperazone is recommended for the treatment of patients with pelvic inflammatory disease, but it will be required further clinical reports.
This study was examined to evaluate the clinical efficacy of the cefbuperazone in 40 patients with pelvic inflammatory disease, who visited the department of obstetrics and gynecology, Yonsei university college of medicine from August 1991 through July 1992. The mean age of the patients was 34.0 years (range 19 to 40 years). The total isolated organisms were 47 strains. Among them the aerobes were 32 strains (68.1%) and the anaerobes were 15 strains (31.9%). Bacteriological response of cefbuperazone was superior than that of ampicllin & cephalothin in vitro susceptability tests. The cefbuperazone was sensitive to all isolated organisms except enterococcus which was more sensitive to ampicillin. Minimum inhibitory concentration (MIC) of cefbuperazone for most of the isolated organisms except enterococcus was less than 4 micro g/ml. The eradication rate, in the bacteriologic response of cefbuperazone, was 82.7%, and the clinical efficacy rate of cefbuperazone was 100%. There was no remarkable side effect. Our results suggest that the cefbuperazone is recommended for the treatment of patients with pelvic inflammatory disease, but it will be required further clinical reports.